Patient and Families Healthcare Professional Contact Us Register Clinic Locator
References
  1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol 3. 8th ed. New York, NY: McGraw-Hill; 2001:3421–3452.
  2. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533-539.
  3. Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A. 2005;134:144–150.
  4. Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr. 2004;144(5 Suppl):S3–S14.
  5. Miller G, Partridge A. Mucopolysaccharidosis type VI presenting in infancy with endocardial fibroelastosis and heart failure. Pediatr Cardiol. 1983;4:61–62.
  6. Smith KS, Hallett KB, Hall RK, Wardrop RW, Firth N. Mucopolysaccharidosis: MPS VI and associated delayed tooth eruption. Int J Oral Maxillofac Surg. 1995;24:176–180.
  7. Vougioukas VI, Berlis A, Kopp MV, Korinthenberg R, Spreer J, van Velthoven V. Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature. Pediatr Neurosurg. 2001;35:35–38.
  8. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254.
  9. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151–156.
  10. Litjens T, Hopwood JJ. Mucopolysaccharidosis type VI: structural and clinical implications of mutations in N-acetylgalactosamine-4 sulfatase. Hum Mutat. 2001; 18:282–295.
  11. Gunin AG. Connective tissue [fact sheet]. Department of histology at the medical school of Chuvash State University. Available at: http://www.histol.chuvashia.com/tab-en/cont-en.htm. Accessed May 8, 2006.
  12. Muenzer J, Fisher A. Advances in the Treatment of Mucopolysaccharidosis Type I. N Engl J Med. 2004;19:1932–1934.
  13. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Childhood. 1995;72:263–267.
  14. Kakkis ED, Neufeld EF. The mucopolysaccharidoses. In: Berg B, ed. Principles of Child Neurology. 1st ed. New York, New York: McGraw-Hill Inc; 1996; 1141–1166.
  15. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681–e689.
  16. Caplan S, Bonifacino JS. Lysosomes. In: Gorvel J-P, ed. Intracellular Pathogens in Membrane Interactions and Vacuole Biogenesis. New York, NY: Kluwer Academic/Plenum Publishers; 2003:16-30.
Privacy Notice PI Download Site Map MPSVI.com References